Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 earnings estimates for Benitec Biopharma in a research report issued to clients and investors on Monday, December 16th. HC Wainwright analyst R. Selvaraju forecasts that the biotechnology company will earn ($0.27) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $28.00 target price on the stock. The consensus estimate for Benitec Biopharma's current full-year earnings is ($4.33) per share. HC Wainwright also issued estimates for Benitec Biopharma's Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.
Several other analysts also recently issued reports on the stock. Piper Sandler reissued an "overweight" rating on shares of Benitec Biopharma in a research report on Friday, October 18th. Robert W. Baird assumed coverage on shares of Benitec Biopharma in a research note on Friday, December 13th. They issued an "outperform" rating and a $30.00 price objective on the stock. Baird R W raised shares of Benitec Biopharma to a "strong-buy" rating in a research report on Thursday, December 12th. Oppenheimer initiated coverage on shares of Benitec Biopharma in a research report on Wednesday, October 16th. They issued an "outperform" rating and a $35.00 price target on the stock. Finally, Guggenheim reissued a "buy" rating and set a $17.00 price objective on shares of Benitec Biopharma in a report on Tuesday, December 3rd. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $24.43.
Read Our Latest Stock Report on BNTC
Benitec Biopharma Price Performance
Shares of Benitec Biopharma stock traded up $0.33 during trading on Thursday, reaching $12.17. 72,178 shares of the company traded hands, compared to its average volume of 46,428. The firm has a market capitalization of $282.54 million, a PE ratio of -4.29 and a beta of 0.88. The company has a 50 day moving average price of $10.77 and a 200-day moving average price of $9.40. Benitec Biopharma has a 1-year low of $2.69 and a 1-year high of $13.29.
Institutional Trading of Benitec Biopharma
Several institutional investors and hedge funds have recently modified their holdings of BNTC. GAMMA Investing LLC increased its stake in Benitec Biopharma by 20.3% in the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company's stock valued at $60,000 after acquiring an additional 1,102 shares during the last quarter. Acuta Capital Partners LLC bought a new position in shares of Benitec Biopharma during the 3rd quarter valued at about $274,000. Simplify Asset Management Inc. purchased a new position in shares of Benitec Biopharma during the 2nd quarter valued at about $358,000. Geode Capital Management LLC raised its holdings in shares of Benitec Biopharma by 31.3% during the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company's stock valued at $772,000 after buying an additional 20,012 shares in the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in Benitec Biopharma in the 2nd quarter worth approximately $5,881,000. Hedge funds and other institutional investors own 52.19% of the company's stock.
Insiders Place Their Bets
In other news, Director Suvretta Capital Management, L acquired 42,000 shares of the business's stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average cost of $9.60 per share, for a total transaction of $403,200.00. Following the completion of the transaction, the director now owns 7,957,365 shares of the company's stock, valued at $76,390,704. The trade was a 0.53 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.30% of the company's stock.
About Benitec Biopharma
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Featured Articles
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
